All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong BuyZacks Investment Research • 11/04/25
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025GlobeNewsWire • 10/31/25
4 High-Earnings Yield Value Picks Ahead of Potential Fed Rate CutZacks Investment Research • 10/29/25
CorMedix: Strong Buy After Strong Developments And A Strategy Before EarningsSeeking Alpha • 10/24/25
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCathGlobeNewsWire • 10/23/25
Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire • 10/22/25
Wall Street Analysts See a 68.59% Upside in CorMedix (CRMD): Can the Stock Really Move This High?Zacks Investment Research • 10/21/25
CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains?Zacks Investment Research • 10/21/25
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?Zacks Investment Research • 10/20/25
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue GuidanceGlobeNewsWire • 10/20/25
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?Zacks Investment Research • 10/14/25
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?Zacks Investment Research • 10/07/25
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYOGlobeNewsWire • 09/29/25
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?Zacks Investment Research • 09/23/25
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?Zacks Investment Research • 09/18/25
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?Zacks Investment Research • 09/15/25
CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 09/09/25